

**Full Program - 70 Drug Classes
PPO and HMO Plans Carved Out to PBM 2016**

Rank	Drug Class	Estimated Reduction in Spending (in millions)
1	Insulins	\$3.4 - \$3.6
2	Skin and Mucous Membrane Agents, Misc	\$2.1 - \$3.0
3	Selective beta-2-Adrenergic Agonists	\$1.9
4	Incretin Mimetics	\$1.7 - \$1.8
5	Anticonvulsants, Miscellaneous	\$1.5 - \$1.6
6	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	\$1.5 - \$1.6
7	Adrenals	\$1.2 - \$1.4
8	Estrogens	\$1.1 - \$1.4
9	Corticosteroids	\$0.8 - \$1.2
10	Atypical Antipsychotics	\$0.7 - \$1.2
11	Opiate Agonists	\$1.2
12	Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors	\$1.1
13	Phosphodiesterase Type 5 Inhibitors	\$1.0
14	Contraceptives	\$0.9
15	Androgens	\$0.8
16	Proton-pump Inhibitors	\$0.8
17	Amphetamines	\$0.7
18	Thyroid Agents	\$0.6
19	Biguanides	\$0.5
20	Angiotensin II Receptor Antagonists	\$0.4
21	Selective Serotonin- and Norepinephrine-reuptake Inhibitors	\$0.4
22	beta-Adrenergic Blocking Agents	\$0.4
23	Selective Serotonin Agonists	\$0.4
24	alpha- and beta-Adrenergic Agonists	\$0.4
25	Antimuscarinics/Antispasmodics	\$0.4
26	HMG-CoA Reductase Inhibitors	\$0.4
27	Nucleosides and Nucleotides	\$0.4
28	Other Nonsteroidal Anti-inflammatory Agents	\$0.3
29	Antiallergic Agents	\$0.3
30	Miscellaneous Antidepressants	\$0.3
31	Serotonin Modulators	\$0.3
32	Opiate Partial Agonists	\$0.3
33	Antilipemic Agents, Miscellaneous	\$0.3

**Full Program - 70 Drug Classes
PPO and HMO Plans Carved Out to PBM 2016**

Rank	Drug Class	Estimated Reduction in Spending (in millions)
34	Platelet-Aggregation Inhibitors	\$0.2
35	Antimuscarinics	\$0.2
36	Antigout Agents	\$0.2
37	Selective Serotonin-reuptake Inhibitors	\$0.2
38	Benzodiazepines	\$0.2
39	Bile Acid Sequestrants	\$0.2
40	Anxiolytics, Sedatives, & Hypnotics Misc	\$0.2
41	Dihydropyridines	\$0.1
42	Fibric Acid Derivatives	\$0.1
43	Prostaglandin Analogs	\$0.1
44	Leukotriene Modifiers	\$0.1
45	Monoamine Oxidase B Inhibitors	\$0.1
46	Bone Resorption Inhibitors	\$0.1
47	Centrally Acting Skeletal Muscle Relaxants	\$0.1
48	Tricyclics and Other Norepinephrine-reuptake Inhibitors	\$0.1
49	Angiotensin-Converting Enzyme Inhibitors	\$0.1
50	Calcium-Channel Blocking Agents, Misc	\$0.1
51	Selective alpha-1-Adrenergic Blocking Agents	\$0.1
52	Nonergot-derivative Dopamine Receptor Agonists	\$0.0
53	Dopamine Precursors	\$0.0
54	Cyclooxygenase-2 (COX-2) Inhibitors	\$0.0
55	Meglitinides	\$0.0
56	Sulfonylureas	\$0.0
57	Thiazolidinediones	\$0.0
58	5-alpha-Reductase Inhibitors	\$0.0
59	Histamine H2-Antagonists	\$0.0
60	5-HT3 Receptor Antagonists	\$0.0
61	Thiazide-like Diuretics	\$0.0
62	Potassium-sparing Diuretics	\$0.0
63	alpha-Adrenergic Blocking Agents	\$0.0
64	Thiazide Diuretics	\$0.0
65	Loop Diuretics	\$0.0
66	Coumarin Derivatives	\$0.0

Full Program - 70 Drug Classes
PPO and HMO Plans Carved Out to PBM 2016

Rank	Drug Class	Estimated Reduction in Spending (in millions)
67	Catechol-O-Methyltransferase (COMT) Inhibitors	\$0.0
68	Second Generation Antihistamines	\$0.0
69	Alpha-Glucosidase Inhibitors	\$0.0
70	Prokinetic Agents	\$0.0
	Total	\$32.1 - \$34.1